Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• Ex vivo genetically engineered cytokine-secreting tumor cell vaccines show potential in preventing metastatic disease in animal models.
• Clinical application is hindered by inefficient gene delivery methods for primary human tumor cells.

Purpose of the Study:

• To develop and evaluate a novel liposome-mediated gene delivery system using adeno-associated virus (AAV)-based plasmids for generating cytokine-secreting tumor cell vaccines.
• To assess the efficacy of these vaccines in preventing metastatic disease in a murine lung cancer model.

Main Methods:

• Liposome-mediated delivery of an AAV-based plasmid encoding murine gamma-interferon (gamma-IFN) into a murine lung cancer cell line (D122).
• Gene transfer efficiency was assessed (10-15%).
• Irradiated D122 cells engineered to secrete gamma-IFN were used as vaccines in tumor-bearing mice, with outcomes compared to control groups and retrovirally modified cells.

Main Results:

• Engineered D122 cells demonstrated high gamma-IFN secretion and elevated MHC class I expression.
• Vaccination with AAV-plasmid-derived gamma-IFN secreting cells significantly delayed tumor growth and reduced pulmonary metastases.
• Fifty-seven percent of animals vaccinated with the novel approach were metastasis-free, a significant improvement over control groups.

Conclusions:

• Liposome-mediated AAV-based plasmid delivery is an effective method for generating cytokine-secreting tumor cell vaccines.
• This novel gene delivery system shows significant promise for clinical application in cancer immunotherapy.
• The approach is adaptable to various tumor types, supporting its translation to clinical trials.